The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 15, 2022
Filed:
May. 13, 2019
Applicant:
Biogen MA Inc., Cambridge, MA (US);
Inventors:
Julie Taylor, San Francisco, CA (US);
Theodore A. Yednock, Forest Knolls, CA (US);
Assignee:
BIOGEN MA INC., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); C07K 16/28 (2006.01); A61K 45/06 (2006.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2839 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2842 (2013.01); G01N 33/56966 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); G01N 2333/4737 (2013.01); G01N 2333/7055 (2013.01);
Abstract
A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.